Corvia Medical, Inc.

Corvia Medical, Inc. is a medical device company based in Tewksbury, Massachusetts, founded in 2009. The company focuses on developing innovative transcatheter cardiovascular devices to improve the treatment of heart failure, particularly heart failure with preserved and mildly reduced ejection fraction. Corvia Medical was previously known as DC Devices, Inc. before rebranding in 2015. The flagship product, the Corvia Atrial Shunt System, is designed to alleviate elevated left atrial pressure in heart failure patients who continue to experience symptoms despite standard medical therapy. This device aims to enhance patients' quality of life by creating a controlled interatrial shunt to relieve pressure in the heart. Corvia Medical is currently conducting the RESPONDER-HF trial, a significant clinical study to gather data for FDA approval of the Atrial Shunt as a treatment for heart failure patients. Corvia Medical serves hospitals, cardiology centers, and healthcare providers specializing in cardiovascular care. The company has raised over $113 million in funding to support its clinical trials and regulatory efforts, employing a small team dedicated to advancing heart failure therapies.

• Employees 39
• Founded 2009
• Annual Revenue $23000000
• Total Funding $160002483